

March 15, 2013



## **Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013**

SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.

Year-to-date, the now fifteen Cancer Index members have posted an average 32% gain (161% Annualized). This is more than double the 15% average YTD appreciation of the NASDAQ, S&P, and NYSE Biotech Indices.

The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first ten weeks of 2013 follow: Galena Biopharma Corporation +39.87%, NewLink Genetics Corporation +0.08%, Vical Incorporated +43.30%, Inovio Pharmaceuticals, Inc. +7.65%, Dendreon (NASDAQ:DNDN) +10.40%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +40.10%, Agenus (NASDAQ:AGEN) +6.59%, Oncothyreon (NASDAQ:ONTY) +15.63%, Biovest International (Pink Sheets:BVTIQ) -56.00%, Celldex Therapeutics (NASDAQ:CLDX) +78.24%, Northwest Biotherapeutics (NASDAQ:NWBO) +17.96%, CEL – SCI Corp. (NYSE MKT:CVM) -4.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets:PVCT) +40.18% and Advaxis, Inc. (OTCBB:ADXS) +199.67% - all for an average 2013 YTD gain of +31.85%. (Annualized rate: 161.48%).

Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at [www.MentorCapital.com](http://www.MentorCapital.com).

**Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.**

Mentor Capital, Inc.  
Chester Billingsley, CEO  
(760) 788-4700

Source: Mentor Capital, Inc.